Paraplatin

(Carboplatin)

ApprovedSmall molecule

Carboplatin is a chemotherapy drug used to treat various cancers, including ovarian cancer, lung cancer, and others. It works by damaging cancer cell DNA to stop them from growing and dividing.[2] Paraplatin is currently approved and in use across 213 indications[4].[1]

Paraplatin is one of 1581 small molecule programs targeting Lymphoma. It is currently in Approved.

213

Indications

2,394

Total Trials

Active Trials

1,580

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

LymphomaTerminated

Endometrial CancerUnknown status

Cervical CancerRecruiting

Triple-Negative Breast CancerCompleted

Esophageal CancerCompleted

Acute Myeloid LeukemiaActive, not recruiting

Uterine CancerTerminated

Non Small Cell Lung Cancer MetastaticNot yet recruiting

EfficacyTerminated

ChemoradiotherapyCompleted

LymphomaPhase 3

Terminated

Endometrial CancerPhase 3

Unknown status

Cervical CancerPhase 3

Recruiting

Triple-Negative Breast CancerPhase 3

Completed

Esophageal CancerPhase 3

Completed

Acute Myeloid LeukemiaPhase 2

Active, not recruiting

Uterine CancerPhase 2

Terminated

Non Small Cell Lung Cancer MetastaticPhase 2

Not yet recruiting

EfficacyPhase 3

Terminated

ChemoradiotherapyPhase 3

Completed

Showing 10 of 212 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Paraplatin

Blenoxane

1 3

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 4

Chantix

PPrism Pharmaceuticals

Preclinical

1 5

Vfend

PPrism Pharmaceuticals

Rilvegostomig

1 7

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 8

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 9

Ablavar

LLantheus Medical Imaging

Preclinical

2 10

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Cervical Cancer

NCT03534713

Phase 2Active, not recruiting

Ovarian Cancer

NCT04274426

Q1 2027

Phase 2Active, not recruiting

Breast Cancer

NCT00616967

Q2 2027

Phase 1/2Recruiting

Clinical Trial

NCT04954599

Q3 2027

Phase 2Recruiting

Immunotherapy

NCT06300424

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer44 trials

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Terminated· Novartis logo

Novartis·Phase 3·NCT04816214·6 enrolled

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03777124·25 enrolled

Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer

Unknown status·PPeople's Hospital of Guangxi Zhuang Autonomous Region·Phase 2·NCT02407366·80 enrolled

Show 41 more trials

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01928160

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Completed· Roche logo

Roche·Phase 3·NCT02657434·578 enrolled

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT01828099·376 enrolled

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03850444·262 enrolled

A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 1·NCT00974584·65 enrolled

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02142738·305 enrolled

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00276588·46 enrolled

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

Recruiting·SShanghai Chest Hospital·Phase 2·NCT06659042·32 enrolled

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Withdrawn· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 3·NCT00055887

Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Unknown status·HHope Cancer Institute, Inc.·Phase 2·NCT00003562·38 enrolled

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00003317·480 enrolled

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00563784·68 enrolled

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Withdrawn·EEastern Cooperative Oncology Group·Phase 2·NCT00469976

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04989283

Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Unknown status·—·Phase 2·NCT00514293·39 enrolled

PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Completed·—·Phase 1·NCT01723800·9 enrolled

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00003313·243 enrolled

Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel

Completed·EECOG-ACRIN Cancer Research Group··NCT00900172·180 enrolled

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Terminated·—·Phase 2·NCT03871153·7 enrolled

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·N/A·NCT02492867·49 enrolled

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT00547443

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT04526691·145 enrolled

Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer

Completed·MMedical Research Council·Phase 3·NCT00003159·600 enrolled

Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 3·NCT00193362·200 enrolled

Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002623·640 enrolled

An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)

Completed·AAktion Bronchialkarzinom e.V.·Phase 1·NCT01683682·8 enrolled

ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Completed· Sanofi logo

Sanofi·Phase 2·NCT00071188

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Withdrawn·IImmunityBio, Inc.·Phase 2·NCT03574649

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Completed· Pfizer logo

Pfizer··NCT05834348·5,279 enrolled

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02477826·2,747 enrolled

Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT02581943·43 enrolled

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Completed· Roche logo

Roche·Phase 3·NCT02409342·572 enrolled

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00112294·755 enrolled

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Completed· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 3·NCT03117049·550 enrolled

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT01041781·313 enrolled

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Terminated· AbbVie logo

AbbVie·Phase 1/2·NCT02412371·48 enrolled

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00041314

Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer

Unknown status·NNational Cancer Institute (NCI)·Phase 2·NCT01507428·138 enrolled

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 2·NCT07256509·120 enrolled

A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)

Terminated· Roche logo

Roche·Phase 3·NCT02409355·8 enrolled

Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery

Completed·FFox Chase Cancer Center··NCT03095209·6 enrolled

Ovarian Cancer17 trials

Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer

Unknown status· GSK logo

GSK·Phase 2·NCT00003733·40 enrolled

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Withdrawn·NNordic Society of Gynaecological Oncology - Clinical Trials Unit·Phase 3·NCT03806049

WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT01144442·10 enrolled

Show 14 more trials

Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT00660842·800 enrolled

Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer

Completed· Sanofi logo

Sanofi··NCT00452985·30 enrolled

A Study LY2228820 for Recurrent Ovarian Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT01663857·118 enrolled

Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT00657878·215 enrolled

Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer

Completed·LLoyola University·Phase 2·NCT00002474

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Terminated·MMorphotek·Phase 3·NCT00849667·1,100 enrolled

BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older

Completed· Roche logo

Roche··NCT02393898·76 enrolled

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting·AAGO Research GmbH·Phase 2·NCT04274426·136 enrolled

INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 3·NCT01379989·617 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Completed·UUniversity of Chicago·Phase 1/2·NCT00003136·11 enrolled

Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT00189566·165 enrolled

Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer

Unknown status·CCytran·Phase 2·NCT00017303

Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03467178·119 enrolled

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Completed·DDavid O'Malley·Phase 1·NCT01220154·9 enrolled

Breast Cancer15 trials

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Recruiting·SShengjing Hospital·Phase 2·NCT05638594·236 enrolled

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT02755272·87 enrolled

Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer

Unknown status·TTheradex·Phase 3·NCT00025688

Show 12 more trials

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Completed· AbbVie logo

AbbVie·Phase 3·NCT02163694·513 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Completed·HHackensack Meridian Health·Phase 2·NCT00004906

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Withdrawn·—·Phase 1/2·NCT00006123

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Completed·—·Phase 2·NCT02978495·154 enrolled

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT02561832·15 enrolled

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

Completed·—·Phase 2·NCT02789657·32 enrolled

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT02605915·98 enrolled

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Terminated·PPamela Munster·Phase 1·NCT02358200·23 enrolled

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00616967·68 enrolled

Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.

Active, not recruiting·CCantargia AB·Phase 1/2·NCT05181462·117 enrolled

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Withdrawn·NNorthwestern University·Phase 1·NCT05093387

Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer

Completed·EEric Winer, MD·Phase 2·NCT00148668·81 enrolled

Neuroblastoma8 trials

Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

Unknown status·UUniversity of Leicester·Phase 3·NCT00030719·175 enrolled

Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

Terminated·MM.D. Anderson Cancer Center·Phase 2/3·NCT00539500·3 enrolled

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma

Unknown status·CChildren's Cancer and Leukaemia Group·N/A·NCT00287950·120 enrolled

Show 5 more trials

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Unknown status·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·Phase 3·NCT00410631·642 enrolled

Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma

Completed·EEuropean Infant Neuroblastoma Study Group - 1999·Phase 2·NCT00025623

Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.

Completed·EEuropean Infant Neuroblastoma Study Group - 1999·Phase 2·NCT00025597

Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma

Completed·—·Phase 3·NCT00002802·500 enrolled

Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma

Completed·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00365755

Small Cell Lung Cancer7 trials

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03066778·453 enrolled

Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03711305·462 enrolled

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00453154·156 enrolled

Show 4 more trials

Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

Completed·SShadia Jalal, MD·Phase 2·NCT03913455·24 enrolled

Immunotherapy as Second-line in Patient With Small Cell Lung Cancer

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT03059667·73 enrolled

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT04951115·6 enrolled

Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00308529·55 enrolled

73 more indications

Fallopian Tube Cancer6 trials

Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination

Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 1/2·NCT03462212·290 enrolled

Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Unknown status·GGynecologic Oncology Group··NCT01366183·290 enrolled

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin

Withdrawn·GGynecologic Oncology Group·Phase 2·NCT00369954

Show 3 more trials

Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT03410784·72 enrolled

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1/2·NCT01402271·88 enrolled

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT02311907·195 enrolled

Lymphoma5 trials

Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

Terminated·GGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH·Phase 1/2·NCT02983097·34 enrolled

Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193505·40 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002982

Show 2 more trials

Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00007865

Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma

Completed·FFox Chase Cancer Center·Phase 1·NCT00005021·17 enrolled

Primary Peritoneal Cancer4 trials

Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Terminated·UUConn Health·Phase 2·NCT00408070·5 enrolled

Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed·GGynecologic Oncology Group·Phase 1·NCT00006235

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Completed·—·Phase 2·NCT00520013·60 enrolled

Show 1 more trial

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Completed·GGynecologic Oncology Group·Phase 1·NCT00005026

Lung Cancer4 trials

Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer

Unknown status·—·Phase 2·NCT00150657·45 enrolled

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT00147537·282 enrolled

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT00482014·120 enrolled

Show 1 more trial

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Active, not recruiting· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT01993810·330 enrolled

Ovarian Epithelial Cancer3 trials

Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer

Completed·UUniversity of Glasgow·Phase 3·NCT00003998·1,050 enrolled

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

Terminated·GGynecologic Oncology Group·Phase 3·NCT00002819

Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer

Unknown status·MMedical Research Council·Phase 3·NCT00002477

Bladder Cancer3 trials

Drug Screening Using IMD in Bladder Cancer

Unknown status·—·Phase 1·NCT06204614·18 enrolled

A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function

Completed·DDr Anders Ullén·Phase 2·NCT02665039·62 enrolled

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01916109·4 enrolled

Esophageal Cancer3 trials

Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation

Unknown status·LLisette Nixon·Phase 2/3·NCT02741856·584 enrolled

Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy

Terminated·—·Phase 2·NCT02392377·1 enrolled

Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

Terminated·SStanford University·Phase 1·NCT00368329·4 enrolled

Pembrolizumab2 trials

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

Completed·AAlliance Foundation Trials, LLC.·Phase 2·NCT02591615·91 enrolled

GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

Active, not recruiting·NNETRIS Pharma·Phase 1/2·NCT04652076·240 enrolled

Blood-Brain Barrier2 trials

Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy

Completed·IInSightec·Phase 1/2·NCT04417088·28 enrolled

Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9

Completed·CCarThera·Phase 1/2·NCT03744026·38 enrolled

Bone Marrow Transplantation2 trials

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Terminated·LLouisiana State University Health Sciences Center Shreveport·Phase 1/2·NCT00003086·12 enrolled

Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors

Completed·UUNICANCER·Phase 3·NCT00002566·280 enrolled

Primitive Neuroectodermal Tumor2 trials

Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors

Completed·CChildren's Oncology Group·Phase 2·NCT00003846·25 enrolled

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Completed·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT00303810·567 enrolled

Stage IV Ovarian Epithelial Cancer2 trials

High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery

Completed·EEBMT Solid Tumors Working Party·Phase 3·NCT00004921

Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer

Completed·AAGO Study Group·Phase 3·NCT00006454

Radiation Therapy2 trials

Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC

Terminated·VVanderbilt-Ingram Cancer Center·Phase 1/2·NCT00544648·13 enrolled

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Completed·SSWOG Cancer Research Network·Phase 2·NCT00055835·7 enrolled

Nab-paclitaxel2 trials

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT04725448·27 enrolled

A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

Unknown status·GGuangdong Association of Clinical Trials·Phase 2·NCT04015778·48 enrolled

Patients With Advanced Solid Tumors2 trials

Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors

Terminated·MMatthew Galsky·Phase 1·NCT01496534·14 enrolled

A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

Terminated·SSyros Pharmaceuticals·Phase 1·NCT03134638·107 enrolled

Metastatic Urothelial Cancer2 trials

A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.

Completed·IInstitut Claudius Regaud·Phase 2/3·NCT02240017·46 enrolled

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Active, not recruiting· Astellas logo

Astellas·Phase 3·NCT04223856·886 enrolled

Endometrial Carcinoma2 trials

END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin

Completed·NNational Cancer Institute, Naples·Phase 2·NCT00401635·42 enrolled

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT04865289·130 enrolled

Glioblastoma Multiforme2 trials

Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors

Completed·NNYU Langone Health·Phase 2·NCT00002619·60 enrolled

Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme

Completed·NNYU Langone Health·Phase 2·NCT00010036

Carboplatin2 trials

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01237067·77 enrolled

A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00343291·121 enrolled

Germ Cell Tumor2 trials

TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors

Recruiting·BBeihua Kong·Phase 3·NCT02429687·129 enrolled

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00423852·26 enrolled

Squamous Cell Carcinoma2 trials

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

Completed·OOncolytics Biotech·Phase 2·NCT00998192·32 enrolled

Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix

Terminated·WWake Forest University Health Sciences·Phase 1·NCT00084890·15 enrolled

Refractory Solid Tumors2 trials

A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00990912·20 enrolled

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01478685·169 enrolled

Esophageal Adenocarcinoma1 trial

Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT02998268·42 enrolled

Cervical Carcinoma1 trial

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06241235·48 enrolled

Treatment1 trial

Treatment of Tumors of the Choroid Plexus Epithelium

Terminated·MM.D. Anderson Cancer Center·Phase 3·NCT00500890·2 enrolled

Head and Neck Cancer1 trial

Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00646659·47 enrolled

Hepatocellular Carcinoma1 trial

Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma

Unknown status·SSun Yat-sen University·Phase 3·NCT02755311·198 enrolled

Mantle Cell Lymphoma1 trial

Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00003541·24 enrolled

Epstein Barr Virus1 trial

Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes

Completed·—·Phase 2·NCT00953420·20 enrolled

Head and Neck Cancers1 trial

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Completed·OOncolytics Biotech·Phase 3·NCT01166542·167 enrolled

Locally Advanced or Metastatic NSCLC1 trial

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT01982955·88 enrolled

Cisplatin1 trial

Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

Completed·WWomen's Cancer Care Associates, LLC·Phase 3·NCT02501954·48 enrolled

Nausea and vomiting1 trial

Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease

Unknown status·JJonsson Comprehensive Cancer Center·Phase 3·NCT00005024

First Line Therapy1 trial

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT03629925·357 enrolled

First-line1 trial

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT02576574·1,214 enrolled

Carcinoma of Unknown Primary1 trial

Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00148135

Advanced Sarcoma1 trial

Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00002974·34 enrolled

Locally Advanced1 trial

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1/2·NCT00021047

Ovarian Carcinoma1 trial

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00059787·56 enrolled

Uterine Cancer1 trial

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

Terminated·—·N/A·NCT01367301·14 enrolled

Cancer of Unknown Primary1 trial

Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin

Unknown status·AAcademisch Ziekenhuis Maastricht·Phase 3·NCT00003558·140 enrolled

Chemotherapy1 trial

A Study on the Efficacy of Atezolizumab Combined with Chemotherapy

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China··NCT06780826·1,430 enrolled

Neoadjuvant Chemotherapy1 trial

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

Not yet recruiting·SShanghai Chest Hospital·Phase 2·NCT06688656·30 enrolled

Clinical Trial1 trial

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Recruiting·MMaastricht University Medical Center·Phase 1/2·NCT04954599·126 enrolled

Advanced NSCLC1 trial

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

Active, not recruiting·LLi Zhang, MD·Phase 3·NCT04695925·294 enrolled

Melanoma1 trial

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00110019·823 enrolled

Cervical Cancer1 trial

Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread

Recruiting·UUniversity Hospital, Toulouse·Phase 3·NCT03534713·310 enrolled

Kidney Cancer1 trial

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003342·30 enrolled

Brain Tumors1 trial

Lobradimil and Carboplatin in Treating Children With Brain Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019422

Malignant Brain Tumors1 trial

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT00238173·2 enrolled

Advanced Solid Tumors1 trial

A Study in Advanced Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01063075·34 enrolled

Pleural Mesothelioma1 trial

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT05136677·102 enrolled

Primary Peritoneal Cavity Cancer1 trial

Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Completed·—·Phase 2/3·NCT00075712·150 enrolled

Endometrial Cancer1 trial

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Completed·GGOG Foundation·Phase 3·NCT00063999·1,381 enrolled

Immunotherapy1 trial

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06300424·32 enrolled

Advanced Cancer1 trial

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003376·330 enrolled

Gynecologic Cancer1 trial

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Completed·FFox Chase Cancer Center·Phase 1·NCT01281514·21 enrolled

Adjuvant Treatment1 trial

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

Unknown status·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT04455594·168 enrolled

Chemoradiotherapy1 trial

Chemoradiotherapy in Elderly Patients With Oesophagus Cancer

Recruiting·—·Phase 1/2·NCT02735057·54 enrolled

Advanced Solid Cancer1 trial

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00535119·107 enrolled

Central Nervous System Lymphoma1 trial

Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Unknown status·OOHSU Knight Cancer Institute·Phase 1/2·NCT00293475·81 enrolled

Metastatic Tumors1 trial

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Completed· Roche logo

Roche·Phase 1·NCT02794571·518 enrolled

Glioma1 trial

A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01445119·58 enrolled

Peritoneal Cancer1 trial

Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Unknown status·LLudwig-Maximilians - University of Munich·Phase 2/3·NCT00045461·241 enrolled

Gastroesophageal Junction1 trial

Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

Completed·MMayo Clinic·Phase 1/2·NCT02730546·31 enrolled

Side Effects1 trial

Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer

Unknown status·CChildren's Cancer and Leukaemia Group··NCT00897871·60 enrolled

Recruiting·RRuijin Hospital·Phase 2·NCT06122493·48 enrolled

Adenocarcinoma1 trial

Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus

Active, not recruiting·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT02509286·438 enrolled

Metastatic Renal Cell Cancer1 trial

Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00077129·22 enrolled

Neoadjuvant Treatment1 trial

Pathological Response After Neoadjuvant Treatment on NSCLC

Recruiting·FFundación GECP··NCT05167487·150 enrolled

Neoadjuvant Therapy1 trial

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06366945·85 enrolled

Regulatory

FDA Approval Timeline[5]

Mar 3, 1989

PARAPLATIN

NDA NDA019880

Jul 14, 2003

PARAPLATIN

NDA NDA020452

Aug 8, 2025

KYXATA

NDA NDA219921

Sources

References

[1]
ClinicalTrials.gov — 2394 trial records for Carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Paraplatin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA219921). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Paraplatin. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Avyxa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AAvyxa

Patent Landscape[6]

Patent Cliff

Apr 1, 2045

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12427104Apr 1, 2045